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Aims: The continuing failure to develop an effective treatment for Alzheimer’s 
disease (AD) reveals the complexity for AD pathology. Increasing evidence 
indicates that neuroinflammation involving particularly microglial cells 
contributes to disease pathogenesis. Here we analyze the differences in the 
microglial response between APP/PS1 model and human brains.  
 
Methods: RT-PCR, western blots, and immunostaining were performed in the 
hippocampus of human post mortem samples (from Braak II to Braak V-VI) and 
APP751SL/PS1M146L mice. In vitro studies to check the effect of S1 fractions 
on microglial cells were assayed. 
Results: In APP based models the high Abeta accumulation triggers a 
prominent microglial response. On the contrary, the microglial response 
detected in human samples is, at least, partial or really mild. This patent 
difference could simple reflect the lower and probably slower Abeta production 
observed in human hippocampal samples, in comparison with models or could 
reflect the consequence of a chronic long-standing microglial activation.  
However, beside this differential response, we also observed a prominent 
microglial degenerative process in Braak V-VI samples that, indeed, could 
compromise their normal role of surveying the brain environment and respond 
to the damage. This microglial degeneration, particularly relevant at the dentate 
gyrus of the hippocampal formation, might be mediated by the accumulation of 
toxic soluble phospho-tau species. 
Conclusions: These differences need to be considered when delineating 
animal models that better integrate the complexity of AD pathology and, 
therefore, guarantee clinical translation. Correcting dysregulated brain 
inflammatory responses might be a promising avenue to restore cognitive 
function. 
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